Latest:
The Future of Endometrial Cancer Treatment
Experts give insight on what they are looking forward to in the endometrial cancer space.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Brady L. Stein, MD
Latest:
Dr. Stein Discusses Changes to the NCCN Guidelines in MPNs
Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).
Brandon G. Smaglo, MD, FACP
Brandon G. Smaglo, MD, FACP, is an associate professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Latest:
Dr Smaglo on Selecting Between Frontline Chemotherapy Regimens for Pancreatic Cancer
Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.
Breanne E. Terakedis, MD
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations
Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate
cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Breelyn A. Wilky, MD
Breelyn Wilky, MD, is the director of Sarcoma Medical Oncology, The Cheryl Bennet and McNeilly Family Endowed Chair in Sarcoma Research, director of Sarcoma Medical Oncology, and deputy associate director for Clinical Research at the University of Colorado Cancer Center – Anschutz Medical Campus.
Latest:
Dr Wilky on the Role of Personalized Therapy in GIST
Breelyn Wilky, MD, details personalized therapy approaches for the treatment of patients with GIST.
Breelyn Wilky, MD
Latest:
Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches
Experts discuss the preliminary results of the PEAK study on the combination of bezuclastinib and sunitinib in second-line gastrointestinal stromal tumors (GIST), its potential to address heterogeneous resistance mutations, and how mutation-specific, biomarker-driven approaches in ongoing trials like INSIGHT may shift the treatment paradigm compared with traditional line-of-therapy strategies.